Ticagrelor NICE guidance

Revision as of 16:08, 1 July 2011 by C Michael Gibson (talk | contribs) (New page: Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 ...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
  Normal  0          false  false  false    EN-US  X-NONE  X-NONE                                       MicrosoftInternetExplorer4                                                                                                                                                                                                                                                                                                                             Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

The NICE guidance regarding the utilzation of Ticagrelor is as follows:" 1.1 Ticagrelor in combination with aspirin is recommended as a treatment option in adults with acute coronary syndromes (ACS) that is, people with:

ST-segment-elevation myocardial infarction (STEMI) – defined as ST elevation or new left bundle branch block on electrocardiogram – that cardiologists intend to treat with primary percutaneous coronary intervention (PCI) or non-ST-segment-elevation myocardial infarction (NSTEMI) or unstable angina – defined as ST or T wave changes on electrocardiogram suggestive of ischaemia and one risk factor for cardiovascular disease (see section 1.2) – in hospitalised patients. After treatment is initiated it should only be continued if the diagnosis is confirmed by a cardiologist.

1.2 For the purposes of this guidance risk factors for cardiovascular disease are: age 60 years or older; previous myocardial infarction; previous coronary artery bypass grafting (CABG); coronary artery disease with stenosis of 50% or more in at least two vessels; previous ischaemic stroke; previous transient ischaemic attack; previous carotid stenosis of at least 50%; previous cerebral revascularisation; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73 m2 of body-surface area.

"

Sources

Template:WH Template:WS